View Older Stories View More Recent Stories

Aug 26, 2019 04:05PM Wave Life Sciences to Present at the Morgan Stanley Global Healthcare Conference
Aug 26, 2019 04:05PM Wave Life Sciences to Present at the Morgan Stanley Global Healthcare Conference
Aug 6, 2019 07:30AM Wave Life Sciences Appoints Mark Baldry as Chief Commercial Officer
Aug 6, 2019 07:30AM Wave Life Sciences Appoints Mark Baldry as Chief Commercial Officer
Jul 29, 2019 04:05PM Wave Life Sciences Reports Second Quarter 2019 Financial Results and Provides Business Update
Jul 29, 2019 04:05PM Wave Life Sciences Reports Second Quarter 2019 Financial Results and Provides Business Update
Jun 27, 2019 08:04AM WAVE Life Sciences (WVE) Commences Initiation of DYSTANCE 51, a Phase 2/3 Clinical Trial of Suvodirsen
Jun 27, 2019 08:00AM Wave Life Sciences Announces Initiation of DYSTANCE 51, a Phase 2/3 Clinical Trial of Suvodirsen
Jun 27, 2019 08:00AM Wave Life Sciences Announces Initiation of DYSTANCE 51, a Phase 2/3 Clinical Trial of Suvodirsen
Jun 12, 2019 08:00AM Wave Life Sciences to Present at Parent Project Muscular Dystrophy 2019 Annual Conference
Jun 12, 2019 08:00AM Wave Life Sciences to Present at Parent Project Muscular Dystrophy 2019 Annual Conference
May 22, 2019 04:15PM Wave Life Sciences to Present at the Jefferies 2019 Healthcare Conference
May 22, 2019 04:15PM Wave Life Sciences to Present at the Jefferies 2019 Healthcare Conference
May 10, 2019 07:30AM Wave Life Sciences Reports First Quarter 2019 Financial Results and Provides Business Update
May 10, 2019 07:30AM Wave Life Sciences Reports First Quarter 2019 Financial Results and Provides Business Update
Apr 16, 2019 07:04AM WAVE Life Sciences (WVE) Announces Positive Suvodirsen Phase 1 Safety and Tolerability Data in DMD
Apr 16, 2019 07:00AM Wave Life Sciences Announces Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design
Apr 16, 2019 07:00AM Wave Life Sciences Announces Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design
Apr 12, 2019 08:00AM Wave Life Sciences to Host Investor Conference Call to Discuss Suvodirsen DMD Clinical Data Being Presented at MDA Clinical and Scientific Conference
Apr 12, 2019 08:00AM Wave Life Sciences to Host Investor Conference Call to Discuss Suvodirsen DMD Clinical Data Being Presented at MDA Clinical and Scientific Conference
Apr 10, 2019 07:00AM Wave Life Sciences Provides Timing Update on PRECISION-HD Clinical Programs
Apr 10, 2019 07:00AM Wave Life Sciences Provides Timing Update on PRECISION-HD Clinical Programs
Mar 25, 2019 08:00AM Wave Life Sciences to Present Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design at the Muscular Dystrophy Association Clinical and Scientific Conference
Mar 25, 2019 08:00AM Wave Life Sciences to Present Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design at the Muscular Dystrophy Association Clinical and Scientific Conference
Mar 6, 2019 08:00AM Wave Life Sciences to Present at the Cowen 39th Annual Health Care Conference
Mar 6, 2019 08:00AM Wave Life Sciences to Present at the Cowen 39th Annual Health Care Conference
Mar 1, 2019 07:30AM Wave Life Sciences Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Business Update
Mar 1, 2019 07:30AM Wave Life Sciences Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Business Update
Feb 12, 2019 01:17PM Pioneer in Taking RNA Therpeutics Through the Clinic Joins Skyhawk Therapeutics as Chief Medical Officer
Jan 3, 2019 08:00AM Wave Life Sciences Duchenne Muscular Dystrophy Clinical Trial Selected for FDA Complex Innovative Trial Designs Pilot Program
Jan 3, 2019 08:00AM Wave Life Sciences Duchenne Muscular Dystrophy Clinical Trial Selected for FDA Complex Innovative Trial Designs Pilot Program
Sep 14, 2016 07:30AM WAVE Life Sciences to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable
Aug 17, 2016 08:00AM WAVE Life Sciences Appoints Keith Regnante as Chief Financial Officer
Aug 15, 2016 04:10PM WAVE Life Sciences Reports Second Quarter 2016 Financial Results and Provides Business Update
Jul 12, 2016 07:30AM WAVE Life Sciences Appoints Dr. Michael Panzara as Head of Neurology Franchise
Jun 27, 2016 06:47PM WAVE Life Sciences Added to the Russell 2000® Index
Jun 21, 2016 07:00AM WAVE Life Sciences Receives Orphan Drug Designation from FDA for its Lead Candidate Designed to Treat Huntington’s Disease
Jun 15, 2016 08:00AM WAVE Life Sciences to Present at the JMP Securities Life Sciences Conference
Jun 1, 2016 07:30AM WAVE Life Sciences to Present at the Jefferies 2016 Healthcare Conference
May 16, 2016 04:30PM WAVE Life Sciences Reports First Quarter 2016 Financial Results and Provides Business Update
May 9, 2016 08:00AM WAVE Life Sciences to Advance Next-Generation Nucleic Acid Therapies to Address Unmet Need in Duchenne Muscular Dystrophy
May 5, 2016 07:01AM WAVE Life Sciences Enters Collaboration with Pfizer to Develop Genetically Targeted Therapies for the Treatment of Metabolic Diseases
Apr 29, 2016 07:30PM WAVE Life Sciences to Present at the Deutsche Bank 41st Annual Health Care Conference
Mar 30, 2016 08:00AM WAVE Life Sciences Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Business Update
Feb 16, 2016 10:00AM WAVE Life Sciences (Nasdaq: WVE) to Ring The Nasdaq Stock Market Opening Bell
Feb 16, 2016 08:00AM WAVE Life Sciences to Present at the SunTrust Robinson Humphrey 2016 Orphan Drug Day Conference
Feb 3, 2016 07:30AM WAVE Life Sciences to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
Jan 29, 2016 07:30AM WAVE Life Sciences Announces Plan to Deliver Six Clinical Programs by 2018
View More Recent Stories View Older Stories